The Bayesian NMA comparing ICIs and Ram+Doc for refractory or relapsed advanced NSCLC in patient groups lacking the PD-L1 status constraint revealed that the OS corresponding to Niv treatment was superior to that of Ram+Doc. Here, CD274 is linked to non-small cell lung carcinoma.